Dinoprostone vaginal slow-release system (Propess®) compared to expectant management in the active treatment of premature rupture of the membranes at term: impact on maternal and fetal outcomes
Background. Retrospective study of 744 women at the Virgen del Camino Hospital in Pamplona concerning two variants for the active treatment of premature rupture of the membranes (PROM). The main purpose of the study was to assess the differences between two variants for the active treatment of PROM...
Gespeichert in:
| Veröffentlicht in: | Acta obstetricia et gynecologica Scandinavica 2008-01, Vol.87 (2), p.195-200 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 200 |
|---|---|
| container_issue | 2 |
| container_start_page | 195 |
| container_title | Acta obstetricia et gynecologica Scandinavica |
| container_volume | 87 |
| creator | Larrañaga-Azcárate, Carlos Campo-Molina, Gema Felicitas Pérez-Rodríguez, Ana Ezcurdia-Gurpegui, Miguel |
| description | Background. Retrospective study of 744 women at the Virgen del Camino Hospital in Pamplona concerning two variants for the active treatment of premature rupture of the membranes (PROM). The main purpose of the study was to assess the differences between two variants for the active treatment of PROM at term in pregnant women with negative vaginal-rectal culture screening for Group B Streptococci, and a Bishop test of 4 or less on admission. Methods. Retrospective study of 744 patients with single pregnancy at term, PROM, and Bishop test |
| doi_str_mv | 10.1080/00016340701837421 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70247045</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70247045</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4659-37db76f838be6be3df13ee71dc5d57d40ce5e30628f62f84cf117a7d2bfa476a3</originalsourceid><addsrcrecordid>eNqFksFu1DAQhiMEokvhAbggX0BwCNhxEnvhVBXYIi0tqkBIXKyJM-6mxHGwnbb7UjxEn6ze7qockOBke_z9M-P5nWVPGX3NqKRvKKWs5iUVlEkuyoLdy2aspjSnJSvuZ7PNfZ6A-V72KITzdCpEKR9me0wWnEkpZ9n1-25wo3chugHJBZx1A_Qk9O4y99gjBCRhHSJa8vKLdyOGcP37FdHOjuCxJdERvBpRRxgisTDAGVpM224gcYUEdOwukESPEG_jzpDRo4U4eSR-Gm_XFNzAFm3jYcBAIJKI3r4lXSqjk2pIuVNk0xoMLTEY085NMfWB4XH2wEAf8Mlu3c--ffzw9fAoX54sPh0eLHNd1tU856JtRG0klw3WDfLWMI4oWKurthJtSTVWyGldSFMXRpbaMCZAtEVjoBQ18P3sxTZvGtevCUNUtgsa-z717KagBC1KQcsqgWwL6jTX4NGo0XcW_FoxqjbGqb-MS5pnu-RTY7H9o9g5lYDnOwCCht6kSeku3HEFZYzzokhcteUuux7X_6-sDk4Wgs6TLt_quuT21Z0O_E9VCy4q9f14oU4rdrr8cfxZlYl_t-MH47yFFUIfVzr9CnXupo1V4R_PvQHzudaY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70247045</pqid></control><display><type>article</type><title>Dinoprostone vaginal slow-release system (Propess®) compared to expectant management in the active treatment of premature rupture of the membranes at term: impact on maternal and fetal outcomes</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Larrañaga-Azcárate, Carlos ; Campo-Molina, Gema ; Felicitas Pérez-Rodríguez, Ana ; Ezcurdia-Gurpegui, Miguel</creator><creatorcontrib>Larrañaga-Azcárate, Carlos ; Campo-Molina, Gema ; Felicitas Pérez-Rodríguez, Ana ; Ezcurdia-Gurpegui, Miguel</creatorcontrib><description>Background. Retrospective study of 744 women at the Virgen del Camino Hospital in Pamplona concerning two variants for the active treatment of premature rupture of the membranes (PROM). The main purpose of the study was to assess the differences between two variants for the active treatment of PROM at term in pregnant women with negative vaginal-rectal culture screening for Group B Streptococci, and a Bishop test of 4 or less on admission. Methods. Retrospective study of 744 patients with single pregnancy at term, PROM, and Bishop test <4. The patients, who were not randomised, were treated with dinoprostone (Propess®) or expectant therapy, according to the physician's choice. Induction with oxytocin was started 12 h after PROM. Qualitative data were analysed using the 2 test, while quantitative data were analysed using the Student's t-test or the Mann-Whitney U-test according to the distribution of the variables. Regression models were applied to correct the biases caused by confounding variables. Results. Of the 744 patients, the cervix of 13% was maturated with pericervical dinoprostone, while 87% were subject to expectant management until 12 h after rupture of the membranes. The time of dilation and the time until labour were significantly shorter in the dinoprostone group (p=0.0). The rate of caesarean sections was also lower in the dinoprostone group at 9.3% compared to 17.6% in the expectant management group, reaching statistical significance (p=0.04). There were no differences in the parameters of fetal well being (Apgar and pH). Conclusions. The use of therapy with dinoprostone in patients with PROM could be a safe method and more effective than expectant management.</description><identifier>ISSN: 0001-6349</identifier><identifier>EISSN: 1600-0412</identifier><identifier>DOI: 10.1080/00016340701837421</identifier><identifier>PMID: 18231888</identifier><identifier>CODEN: AOGSAE</identifier><language>eng</language><publisher>Oxford, UK: Informa UK Ltd</publisher><subject>Administration, Intravaginal ; Adult ; Anti-Bacterial Agents - therapeutic use ; Biological and medical sciences ; caesarean section ; Cesarean Section - statistics & numerical data ; Delayed-Action Preparations - therapeutic use ; Delivery. Postpartum. Lactation ; Dinoprostone ; Dinoprostone - therapeutic use ; Diseases of mother, fetus and pregnancy ; Disorders ; Female ; Fetal Membranes, Premature Rupture - therapy ; Fever - drug therapy ; Gynecology. Andrology. Obstetrics ; Humans ; Labor Stage, First ; Labor, Induced ; Linear Models ; Medical sciences ; Oxytocics - therapeutic use ; Oxytocin - therapeutic use ; Parity ; Pregnancy ; Pregnancy. Fetus. Placenta ; premature rupture of the membranes ; prostaglandin ; Retrospective Studies ; Time Factors</subject><ispartof>Acta obstetricia et gynecologica Scandinavica, 2008-01, Vol.87 (2), p.195-200</ispartof><rights>2008 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2008</rights><rights>Acta Obstet Gynecol Scand 2008</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4659-37db76f838be6be3df13ee71dc5d57d40ce5e30628f62f84cf117a7d2bfa476a3</citedby><cites>FETCH-LOGICAL-c4659-37db76f838be6be3df13ee71dc5d57d40ce5e30628f62f84cf117a7d2bfa476a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1080%2F00016340701837421$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1080%2F00016340701837421$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20113322$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18231888$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Larrañaga-Azcárate, Carlos</creatorcontrib><creatorcontrib>Campo-Molina, Gema</creatorcontrib><creatorcontrib>Felicitas Pérez-Rodríguez, Ana</creatorcontrib><creatorcontrib>Ezcurdia-Gurpegui, Miguel</creatorcontrib><title>Dinoprostone vaginal slow-release system (Propess®) compared to expectant management in the active treatment of premature rupture of the membranes at term: impact on maternal and fetal outcomes</title><title>Acta obstetricia et gynecologica Scandinavica</title><addtitle>Acta Obstet Gynecol Scand</addtitle><description>Background. Retrospective study of 744 women at the Virgen del Camino Hospital in Pamplona concerning two variants for the active treatment of premature rupture of the membranes (PROM). The main purpose of the study was to assess the differences between two variants for the active treatment of PROM at term in pregnant women with negative vaginal-rectal culture screening for Group B Streptococci, and a Bishop test of 4 or less on admission. Methods. Retrospective study of 744 patients with single pregnancy at term, PROM, and Bishop test <4. The patients, who were not randomised, were treated with dinoprostone (Propess®) or expectant therapy, according to the physician's choice. Induction with oxytocin was started 12 h after PROM. Qualitative data were analysed using the 2 test, while quantitative data were analysed using the Student's t-test or the Mann-Whitney U-test according to the distribution of the variables. Regression models were applied to correct the biases caused by confounding variables. Results. Of the 744 patients, the cervix of 13% was maturated with pericervical dinoprostone, while 87% were subject to expectant management until 12 h after rupture of the membranes. The time of dilation and the time until labour were significantly shorter in the dinoprostone group (p=0.0). The rate of caesarean sections was also lower in the dinoprostone group at 9.3% compared to 17.6% in the expectant management group, reaching statistical significance (p=0.04). There were no differences in the parameters of fetal well being (Apgar and pH). Conclusions. The use of therapy with dinoprostone in patients with PROM could be a safe method and more effective than expectant management.</description><subject>Administration, Intravaginal</subject><subject>Adult</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>caesarean section</subject><subject>Cesarean Section - statistics & numerical data</subject><subject>Delayed-Action Preparations - therapeutic use</subject><subject>Delivery. Postpartum. Lactation</subject><subject>Dinoprostone</subject><subject>Dinoprostone - therapeutic use</subject><subject>Diseases of mother, fetus and pregnancy</subject><subject>Disorders</subject><subject>Female</subject><subject>Fetal Membranes, Premature Rupture - therapy</subject><subject>Fever - drug therapy</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Labor Stage, First</subject><subject>Labor, Induced</subject><subject>Linear Models</subject><subject>Medical sciences</subject><subject>Oxytocics - therapeutic use</subject><subject>Oxytocin - therapeutic use</subject><subject>Parity</subject><subject>Pregnancy</subject><subject>Pregnancy. Fetus. Placenta</subject><subject>premature rupture of the membranes</subject><subject>prostaglandin</subject><subject>Retrospective Studies</subject><subject>Time Factors</subject><issn>0001-6349</issn><issn>1600-0412</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFksFu1DAQhiMEokvhAbggX0BwCNhxEnvhVBXYIi0tqkBIXKyJM-6mxHGwnbb7UjxEn6ze7qockOBke_z9M-P5nWVPGX3NqKRvKKWs5iUVlEkuyoLdy2aspjSnJSvuZ7PNfZ6A-V72KITzdCpEKR9me0wWnEkpZ9n1-25wo3chugHJBZx1A_Qk9O4y99gjBCRhHSJa8vKLdyOGcP37FdHOjuCxJdERvBpRRxgisTDAGVpM224gcYUEdOwukESPEG_jzpDRo4U4eSR-Gm_XFNzAFm3jYcBAIJKI3r4lXSqjk2pIuVNk0xoMLTEY085NMfWB4XH2wEAf8Mlu3c--ffzw9fAoX54sPh0eLHNd1tU856JtRG0klw3WDfLWMI4oWKurthJtSTVWyGldSFMXRpbaMCZAtEVjoBQ18P3sxTZvGtevCUNUtgsa-z717KagBC1KQcsqgWwL6jTX4NGo0XcW_FoxqjbGqb-MS5pnu-RTY7H9o9g5lYDnOwCCht6kSeku3HEFZYzzokhcteUuux7X_6-sDk4Wgs6TLt_quuT21Z0O_E9VCy4q9f14oU4rdrr8cfxZlYl_t-MH47yFFUIfVzr9CnXupo1V4R_PvQHzudaY</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Larrañaga-Azcárate, Carlos</creator><creator>Campo-Molina, Gema</creator><creator>Felicitas Pérez-Rodríguez, Ana</creator><creator>Ezcurdia-Gurpegui, Miguel</creator><general>Informa UK Ltd</general><general>Blackwell Publishing Ltd</general><general>Taylor & Francis</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080101</creationdate><title>Dinoprostone vaginal slow-release system (Propess®) compared to expectant management in the active treatment of premature rupture of the membranes at term: impact on maternal and fetal outcomes</title><author>Larrañaga-Azcárate, Carlos ; Campo-Molina, Gema ; Felicitas Pérez-Rodríguez, Ana ; Ezcurdia-Gurpegui, Miguel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4659-37db76f838be6be3df13ee71dc5d57d40ce5e30628f62f84cf117a7d2bfa476a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Administration, Intravaginal</topic><topic>Adult</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>caesarean section</topic><topic>Cesarean Section - statistics & numerical data</topic><topic>Delayed-Action Preparations - therapeutic use</topic><topic>Delivery. Postpartum. Lactation</topic><topic>Dinoprostone</topic><topic>Dinoprostone - therapeutic use</topic><topic>Diseases of mother, fetus and pregnancy</topic><topic>Disorders</topic><topic>Female</topic><topic>Fetal Membranes, Premature Rupture - therapy</topic><topic>Fever - drug therapy</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Labor Stage, First</topic><topic>Labor, Induced</topic><topic>Linear Models</topic><topic>Medical sciences</topic><topic>Oxytocics - therapeutic use</topic><topic>Oxytocin - therapeutic use</topic><topic>Parity</topic><topic>Pregnancy</topic><topic>Pregnancy. Fetus. Placenta</topic><topic>premature rupture of the membranes</topic><topic>prostaglandin</topic><topic>Retrospective Studies</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Larrañaga-Azcárate, Carlos</creatorcontrib><creatorcontrib>Campo-Molina, Gema</creatorcontrib><creatorcontrib>Felicitas Pérez-Rodríguez, Ana</creatorcontrib><creatorcontrib>Ezcurdia-Gurpegui, Miguel</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta obstetricia et gynecologica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Larrañaga-Azcárate, Carlos</au><au>Campo-Molina, Gema</au><au>Felicitas Pérez-Rodríguez, Ana</au><au>Ezcurdia-Gurpegui, Miguel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dinoprostone vaginal slow-release system (Propess®) compared to expectant management in the active treatment of premature rupture of the membranes at term: impact on maternal and fetal outcomes</atitle><jtitle>Acta obstetricia et gynecologica Scandinavica</jtitle><addtitle>Acta Obstet Gynecol Scand</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>87</volume><issue>2</issue><spage>195</spage><epage>200</epage><pages>195-200</pages><issn>0001-6349</issn><eissn>1600-0412</eissn><coden>AOGSAE</coden><abstract>Background. Retrospective study of 744 women at the Virgen del Camino Hospital in Pamplona concerning two variants for the active treatment of premature rupture of the membranes (PROM). The main purpose of the study was to assess the differences between two variants for the active treatment of PROM at term in pregnant women with negative vaginal-rectal culture screening for Group B Streptococci, and a Bishop test of 4 or less on admission. Methods. Retrospective study of 744 patients with single pregnancy at term, PROM, and Bishop test <4. The patients, who were not randomised, were treated with dinoprostone (Propess®) or expectant therapy, according to the physician's choice. Induction with oxytocin was started 12 h after PROM. Qualitative data were analysed using the 2 test, while quantitative data were analysed using the Student's t-test or the Mann-Whitney U-test according to the distribution of the variables. Regression models were applied to correct the biases caused by confounding variables. Results. Of the 744 patients, the cervix of 13% was maturated with pericervical dinoprostone, while 87% were subject to expectant management until 12 h after rupture of the membranes. The time of dilation and the time until labour were significantly shorter in the dinoprostone group (p=0.0). The rate of caesarean sections was also lower in the dinoprostone group at 9.3% compared to 17.6% in the expectant management group, reaching statistical significance (p=0.04). There were no differences in the parameters of fetal well being (Apgar and pH). Conclusions. The use of therapy with dinoprostone in patients with PROM could be a safe method and more effective than expectant management.</abstract><cop>Oxford, UK</cop><pub>Informa UK Ltd</pub><pmid>18231888</pmid><doi>10.1080/00016340701837421</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-6349 |
| ispartof | Acta obstetricia et gynecologica Scandinavica, 2008-01, Vol.87 (2), p.195-200 |
| issn | 0001-6349 1600-0412 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70247045 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Administration, Intravaginal Adult Anti-Bacterial Agents - therapeutic use Biological and medical sciences caesarean section Cesarean Section - statistics & numerical data Delayed-Action Preparations - therapeutic use Delivery. Postpartum. Lactation Dinoprostone Dinoprostone - therapeutic use Diseases of mother, fetus and pregnancy Disorders Female Fetal Membranes, Premature Rupture - therapy Fever - drug therapy Gynecology. Andrology. Obstetrics Humans Labor Stage, First Labor, Induced Linear Models Medical sciences Oxytocics - therapeutic use Oxytocin - therapeutic use Parity Pregnancy Pregnancy. Fetus. Placenta premature rupture of the membranes prostaglandin Retrospective Studies Time Factors |
| title | Dinoprostone vaginal slow-release system (Propess®) compared to expectant management in the active treatment of premature rupture of the membranes at term: impact on maternal and fetal outcomes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T18%3A18%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dinoprostone%20vaginal%20slow-release%20system%20(Propess%C2%AE)%20compared%20to%20expectant%20management%20in%20the%20active%20treatment%20of%20premature%20rupture%20of%20the%20membranes%20at%20term:%20impact%20on%20maternal%20and%20fetal%20outcomes&rft.jtitle=Acta%20obstetricia%20et%20gynecologica%20Scandinavica&rft.au=Larra%C3%B1aga-Azc%C3%A1rate,%20Carlos&rft.date=2008-01-01&rft.volume=87&rft.issue=2&rft.spage=195&rft.epage=200&rft.pages=195-200&rft.issn=0001-6349&rft.eissn=1600-0412&rft.coden=AOGSAE&rft_id=info:doi/10.1080/00016340701837421&rft_dat=%3Cproquest_cross%3E70247045%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70247045&rft_id=info:pmid/18231888&rfr_iscdi=true |